Peptide Regulation Around the World: Legal Status in the US, EU, UK, and Australia

Peptide Regulation Around the World: Legal Status in the US, EU, UK, and Australia

Peptides occupy a complex regulatory space between small-molecule drugs, biologics, and dietary supplements. Understanding how different jurisdictions classify these molecules is essential for researchers, clinicians, and institutions navigating legal access pathways. The Peptide Register documents regulatory status as part of its independent research reference mission, helping clarify where peptides sit legally in major markets.

This post examines how the United States, European Union, United Kingdom, and Australia regulate therapeutic peptides, with particular attention to prescription requirements, compounding restrictions, and enforcement trends.

United States: FDA Oversight and the Compounding Question

In the United States, most bioactive signalling peptides are regulated as investigational new drugs under the Food and Drug Administration. Peptides such as BPC-157, CJC-1295, and ipamorelin are not approved for human use by the FDA and cannot be legally marketed as drugs or dietary supplements.

The FDA regulates most bioactive signalling peptides as unapproved drugs, meaning they cannot be legally sold for human consumption in the US. Some clinics and compounding pharmacies have historically offered peptides under the framework of physician-prescribed compounding, but the FDA's 2024 Category 1 and 2 guidance sharply restricted this practice. Peptides listed under Category 1 cannot be compounded because FDA-approved alternatives exist or because they pose safety concerns.

Peptides such as semaglutide and tesamorelin are FDA-approved prescription drugs, available only through licensed healthcare providers. Other peptides, including thymosin beta-4 and melanotan II, remain in regulatory limbo: not approved, but widely available through grey-market vendors operating outside FDA jurisdiction. The FDA has issued warning letters to companies marketing unapproved peptides, emphasising that legality hinges on approval status, not marketing claims.

Collagen peptides, derived from hydrolysed gelatin, fall under a separate regulatory pathway and are generally recognized as safe for use in foods and supplements.

European Union and United Kingdom: Medicines Agency Frameworks

In the European Union, peptides are regulated by the European Medicines Agency under the centralized approval process for biological medicinals. Therapeutic peptides require marketing authorisation and are classified as prescription-only medicines unless explicitly exempted. Individual EU member states may impose additional national restrictions.

The EMA classifies therapeutic peptides as prescription-only biological medicines, requiring marketing authorisation for legal sale in the EU. Peptides approved by the EMA include liraglutide, teriparatide, and octreotide, all of which are available only through prescription. Non-approved peptides cannot be legally marketed or sold for human use, though enforcement varies by member state.

In the United Kingdom, post-Brexit, the Medicines and Healthcare products Regulatory Agency maintains similar standards. Peptides are classified as prescription-only medicines, and only MHRA-approved products can be legally prescribed. The MHRA classifies peptides as prescription-only medicines, with enforcement targeting online vendors and unlicensed importation. Compounding is permitted under narrower circumstances than in the US, typically limited to patient-specific prescriptions and unavailable licensed products. The MHRA has actively issued warnings about online peptide suppliers and the risks associated with unregulated peptide products.

Both the EU and UK frameworks emphasize that peptides are medicinal products by function, regardless of how they are marketed. This means that substances presented for treating or preventing disease fall under medicines regulation, even if sold as research chemicals.

Australia: TGA Scheduling and Recent Enforcement Shifts

Australia's Therapeutic Goods Administration employs a scheduling framework that categorizes substances by access restrictions. Most bioactive peptides are classified as Schedule 4 (Prescription Only Medicine) or higher, meaning legal access requires a prescription from a registered medical practitioner.

The TGA classifies most bioactive peptides as Schedule 4 substances, requiring a prescription from a registered practitioner for legal access in Australia. What is Schedule 4? explains the technical classification in detail. The TGA has also implemented specific scheduling changes affecting peptide compounding and importation, documented in TGA peptide scheduling changes.

The TGA's scheduling decisions are informed by the Advisory Committee on Medicines Scheduling, which evaluates risk of misuse, potential for harm, and therapeutic necessity. Peptides such as TB-500, BPC-157, and growth hormone secretagogues are Schedule 4, while some analogues carry higher restrictions.

Australia permits compounding of scheduled peptides under strict conditions: a prescription must be patient-specific, and the peptide must not be on the TGA's exclusion list. The TGA has recently increased enforcement against grey-market suppliers and pharmacies compounding peptides without lawful authority. How to access peptides legally in Australia provides a detailed overview of lawful pathways for clinicians and patients.

The TGA has also responded to international regulatory trends, including the FDA Category 1 impact on Australian compounding, which has influenced local supply chains and prescribing patterns.

Enforcement, Grey Markets, and Regulatory Convergence

Across all four jurisdictions, regulatory agencies are increasing scrutiny of grey-market peptide sales. Online vendors marketing peptides as research chemicals or not for human consumption do not exempt those products from medicines regulation if they are in fact used by humans. Enforcement actions include seizures, warning letters, and prosecution of unlicensed vendors.

The grey market versus prescription distinction is central to understanding risk. Peptides obtained without prescription carry legal, quality, and safety risks that are largely absent in regulated pharmaceutical supply chains. The Peptide Register's grey market monitoring tracks enforcement trends and regulatory updates across jurisdictions.

Regulatory convergence is underway, particularly around peptides previously available via compounding. Both the FDA and TGA have curtailed compounding access for peptides with approved alternatives, and the MHRA maintains a restrictive stance on magistral preparation. This trend reflects a policy preference for approved, quality-controlled products over compounded or grey-market alternatives.

Researchers and clinicians seeking access to peptides must navigate jurisdiction-specific frameworks, verify prescriber authority, and source products through lawful channels. The Peptide Register provides structured peptide profiles including regulatory status by region, helping institutions and practitioners make informed, compliant decisions.